Brief: Imricor Medical Systems Got US FDA Approval For IDE To Initiate Clinical Trial In Us For Visabl-Alf
24/01/2023 24:25
Jan 24 (Reuters) - Imricor Medical Systems Inc IMR.AX :
* GOT APPROVAL FROM US FDA FOR INVESTIGATIONAL DEVICE
EXCEPTION TO
INITIATE CLINICAL TRIAL IN US FOR VISABL-ALF
Source text for Eikon: ID:nASX26vphF
Further company coverage: IMR.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imricor Medical Systems
See all newsBrief: Imricor Medical Systems Says FDA Completes Review Of Imricor's Third PMA Module
Brief: Imricor Medical Systems Says FDA Accepts Imricor Pma Manufacturing Module
Brief: Imricor Medical Systems Says Anticipated FDA Clearances Of Additional Capital Equipment Expected To Broaden Product Offering Available To U.S. Customers
Imricor Medical Systems hits 3-month high on securing first US hospital customer
Brief: Imricor Medical Systems, Receives FDA 510(K) Clearance For Northstar Pediatric Label Expansion